MOESM2 of Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer

434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database

Karapetis, C. S.
Liu, H.
Sorich, M.
Fiskum, J.
Grothey, A.
Adams, R. A.
Venook, A.
Heinemann, V.
Lenz, H. J.
Yoshino, T.
Zalcberg, J. R.
Chibaudel, B.
Buyse, M. E.
De Gramont, A.
Shi, Q.

September 2020

Background Chemotherapy combined with either VEGF or EGFR targeting mAbs improves survival of patien...

EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Srivatsa, S
Paul, Mc
Cardone, C
Holcmann, M
Amberg, N
Pathria, P
Diamanti, Ma
Linder, M
Timelthaler, G
Dienes, Hp
Kenner, L
Wrba, F
Prager, Gw
Rose John, S
Eferl, R
Liguori, G
Botti, G
MARTINELLI, Erika
Greten, Fr
CIARDIELLO, Fortunato
Sibilia, M.

January 2017

Background & aims: Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line ...

MOESM1 of The TGFÎ˛-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs

Andrew Pellatt (5495246)
Lila Mullany (5495249)
Jennifer Herrick (413154)
Lori Sakoda (5495243)
Roger Wolff (3471188)
Wade Samowitz (5495240)
Martha Slattery (3471191)

July 2018

Additional file 1. Table S1: Genes in KEGG TGFBeta-Signaling Pathway. Table S2. Differentially expre...

Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer

Larsson, Anna H.
Lehn, Sophie
Wangefjord, Sakarias
Karnevi, Emelie
Kuteeva, Eugenia
Sundström, Magnus
Nodin, Björn
Uhlen, Mathias
Eberhard, Jakob
Birgisson, Helgi
Jirström, Karin

January 2016

Background: Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demon...

Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas

Heby, Margareta
Karnevi, Emelie
Elebro, Jacob
Nodin, Björn
Eberhard, Jakob
Saukkonen, Kapo
Hagström, Jaana
Mustonen, Harri
Seppänen, Hanna
Haglund, Caj
Jirström, Karin
Larsson, Anna H.

January 2020

The outcome of periampullary adenocarcinomas remains poor with few treatment options. Podocalyxin-li...

Discovery and validation of podocalyxin-like protein as a prognostic biomarker in colorectal cancer

Larsson, Anna H

January 2015

Colorectal cancer (CRC) is the third most common cancer worldwide with more than 700,000 deaths ever...

Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer

Larsson, Anna
Fridberg, Marie
Gaber, Alexander
Nodin, Björn
Leveen, Per
Jönsson, Göran
Uhlen, Mathias
Birgisson, Helgi
Jirström, Karin

January 2012

Background: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has...

References

Spano Jp
Lagorce C
Goldstein Ns

January 2005

receptor status in primary colorectal tumors does not correlate with EGFR expression in related meta...

MOESM3 of Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

David Borg (2157514)
Anna Larsson (2557921)
Charlotta Hedner (2157520)
Bjรถrn Nodin (3439559)
Anders Johnsson (2193301)
Karin Jirstrรถm (3439556)

October 2018

Additional file 3: Table S3. Correlation of PODXL score/expression between whole tissue sections and...

Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer.

Jagt, M. van der
Sweep, C.G.J.
Waas, E.T.
Hendriks, T.
Ruers, T.J.M.
Merry, A.H.
Wobbes, T.
Span, P.N.

January 2006

Contains fulltext : 51160.pdf (publisher's version ) (Closed access)mRNA, and late...

MOESM2 of Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway

Yi Pan (68170)
Siu Cheung (3586919)
Joanna Tong (3761071)
Ka Tin (5338058)
Wei Kang (175399)
Raymond Lung (5338052)
Feng Wu (3098874)
Hui Li (32376)
Simon Ng (1438471)
Tony Mak (5338055)
Ka To (3761077)
Anthony Chan (277898)

June 2018

Additional file 2. Clinicopathological factors predicted prognosis for 190 CRC patients

MOESM4 of Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

David Borg (2157514)
Anna Larsson (2557921)
Charlotta Hedner (2157520)
Bjรถrn Nodin (3439559)
Anders Johnsson (2193301)
Karin Jirstrรถm (3439556)

October 2018

Additional file 4: Table S4. Associations of PODXL expression with clinicopathological factors in th...

EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach

Loupakis F
Vasile E
Santini D
Masi G
Falcone A
Graziano F

January 2008

Monoclonal antibodies directed against the EGF-receptor (EGFR) have recently been approved for the t...

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

McKay, JA
Murray, LJ
Curran, S
Ross, VG
Clark, C
Murray, GI
Cassidy, J
McLeod, HL

January 2002

Overexpression of the epidermal growth factor receptor (EGFR) often correlates with an aggressive tu...

Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: A case report and review of the literature

M. Moroni
S. Veronese
A. Sartore-Bianchi
S. Artale
S. Siena

January 2008

Clinical studies showed that only 10% of patients with metastatic colorectal cancer (mCRC) respond t...

434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database

Karapetis, C. S.
Liu, H.
Sorich, M.
Fiskum, J.
Grothey, A.
Adams, R. A.
Venook, A.
Heinemann, V.
Lenz, H. J.
Yoshino, T.
Zalcberg, J. R.
Chibaudel, B.
Buyse, M. E.
De Gramont, A.
Shi, Q.

September 2020

Background Chemotherapy combined with either VEGF or EGFR targeting mAbs improves survival of patien...

EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Srivatsa, S
Paul, Mc
Cardone, C
Holcmann, M
Amberg, N
Pathria, P
Diamanti, Ma
Linder, M
Timelthaler, G
Dienes, Hp
Kenner, L
Wrba, F
Prager, Gw
Rose John, S
Eferl, R
Liguori, G
Botti, G
MARTINELLI, Erika
Greten, Fr
CIARDIELLO, Fortunato
Sibilia, M.

January 2017

Background & aims: Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line ...

MOESM1 of The TGFÎ˛-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs

Andrew Pellatt (5495246)
Lila Mullany (5495249)
Jennifer Herrick (413154)
Lori Sakoda (5495243)
Roger Wolff (3471188)
Wade Samowitz (5495240)
Martha Slattery (3471191)

July 2018

Additional file 1. Table S1: Genes in KEGG TGFBeta-Signaling Pathway. Table S2. Differentially expre...

Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer

Larsson, Anna H.
Lehn, Sophie
Wangefjord, Sakarias
Karnevi, Emelie
Kuteeva, Eugenia
Sundström, Magnus
Nodin, Björn
Uhlen, Mathias
Eberhard, Jakob
Birgisson, Helgi
Jirström, Karin

January 2016

Background: Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demon...

Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas

Heby, Margareta
Karnevi, Emelie
Elebro, Jacob
Nodin, Björn
Eberhard, Jakob
Saukkonen, Kapo
Hagström, Jaana
Mustonen, Harri
Seppänen, Hanna
Haglund, Caj
Jirström, Karin
Larsson, Anna H.

January 2020

The outcome of periampullary adenocarcinomas remains poor with few treatment options. Podocalyxin-li...

Discovery and validation of podocalyxin-like protein as a prognostic biomarker in colorectal cancer

Larsson, Anna H

January 2015

Colorectal cancer (CRC) is the third most common cancer worldwide with more than 700,000 deaths ever...

Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer

Larsson, Anna
Fridberg, Marie
Gaber, Alexander
Nodin, Björn
Leveen, Per
Jönsson, Göran
Uhlen, Mathias
Birgisson, Helgi
Jirström, Karin

January 2012

Background: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has...

References

Spano Jp
Lagorce C
Goldstein Ns

January 2005

receptor status in primary colorectal tumors does not correlate with EGFR expression in related meta...

MOESM3 of Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

David Borg (2157514)
Anna Larsson (2557921)
Charlotta Hedner (2157520)
Bjรถrn Nodin (3439559)
Anders Johnsson (2193301)
Karin Jirstrรถm (3439556)

October 2018

Additional file 3: Table S3. Correlation of PODXL score/expression between whole tissue sections and...

Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer.

Jagt, M. van der
Sweep, C.G.J.
Waas, E.T.
Hendriks, T.
Ruers, T.J.M.
Merry, A.H.
Wobbes, T.
Span, P.N.

January 2006

Contains fulltext : 51160.pdf (publisher's version ) (Closed access)mRNA, and late...

MOESM2 of Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway

Yi Pan (68170)
Siu Cheung (3586919)
Joanna Tong (3761071)
Ka Tin (5338058)
Wei Kang (175399)
Raymond Lung (5338052)
Feng Wu (3098874)
Hui Li (32376)
Simon Ng (1438471)
Tony Mak (5338055)
Ka To (3761077)
Anthony Chan (277898)

June 2018

Additional file 2. Clinicopathological factors predicted prognosis for 190 CRC patients

MOESM4 of Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

David Borg (2157514)
Anna Larsson (2557921)
Charlotta Hedner (2157520)
Bjรถrn Nodin (3439559)
Anders Johnsson (2193301)
Karin Jirstrรถm (3439556)

October 2018

Additional file 4: Table S4. Associations of PODXL expression with clinicopathological factors in th...

EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach

Loupakis F
Vasile E
Santini D
Masi G
Falcone A
Graziano F

January 2008

Monoclonal antibodies directed against the EGF-receptor (EGFR) have recently been approved for the t...

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

McKay, JA
Murray, LJ
Curran, S
Ross, VG
Clark, C
Murray, GI
Cassidy, J
McLeod, HL

January 2002

Overexpression of the epidermal growth factor receptor (EGFR) often correlates with an aggressive tu...

Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: A case report and review of the literature

M. Moroni
S. Veronese
A. Sartore-Bianchi
S. Artale
S. Siena

January 2008

Clinical studies showed that only 10% of patients with metastatic colorectal cancer (mCRC) respond t...

434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database

Karapetis, C. S.
Liu, H.
Sorich, M.
Fiskum, J.
Grothey, A.
Adams, R. A.
Venook, A.
Heinemann, V.
Lenz, H. J.
Yoshino, T.
Zalcberg, J. R.
Chibaudel, B.
Buyse, M. E.
De Gramont, A.
Shi, Q.

September 2020

Background Chemotherapy combined with either VEGF or EGFR targeting mAbs improves survival of patien...

EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Srivatsa, S
Paul, Mc
Cardone, C
Holcmann, M
Amberg, N
Pathria, P
Diamanti, Ma
Linder, M
Timelthaler, G
Dienes, Hp
Kenner, L
Wrba, F
Prager, Gw
Rose John, S
Eferl, R
Liguori, G
Botti, G
MARTINELLI, Erika
Greten, Fr
CIARDIELLO, Fortunato
Sibilia, M.

January 2017

Background & aims: Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line ...

MOESM1 of The TGFÎ˛-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs

Andrew Pellatt (5495246)
Lila Mullany (5495249)
Jennifer Herrick (413154)
Lori Sakoda (5495243)
Roger Wolff (3471188)
Wade Samowitz (5495240)
Martha Slattery (3471191)

July 2018

Additional file 1. Table S1: Genes in KEGG TGFBeta-Signaling Pathway. Table S2. Differentially expre...

MOESM2 of Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer

Abstract

Extracted data

MOESM2 of Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer

Abstract

Extracted data

Related items

Related items